New combo therapy aims to stop deadly liver Cancer's return
NCT ID NCT07331883
Summary
This study is testing a two-drug combination (sintilimab and a bevacizumab biosimilar) given after surgery to see if it can prevent liver cancer from coming back. It focuses on a dangerous situation where the liver tumor has ruptured, which greatly increases the risk of the cancer returning. The goal is to see if this treatment is safe and effective for patients who have had their ruptured tumor surgically removed.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Huashan Hospital, Fudan University
RECRUITINGShanghai, Shanghai Municipality, 200031, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, 200025, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Sanming First Hospital
NOT_YET_RECRUITINGSanming, Fujian, 365000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The Third Bethune Hospital of Jilin University
RECRUITINGChangchun, Jilin, 130033, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.